A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Emtricitabine and Descovy in Patients With Mild Cognitive Impairment.
Latest Information Update: 15 Oct 2025
At a glance
- Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir alafenamide (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions
- Acronyms SONATAS
Most Recent Events
- 15 Oct 2025 New trial record